287 related articles for article (PubMed ID: 14665864)
21. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
[TBL] [Abstract][Full Text] [Related]
22. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup.
Sanderson KM; Cai J; Miranda G; Skinner DG; Stein JP
J Urol; 2007 Jun; 177(6):2088-94. PubMed ID: 17509294
[TBL] [Abstract][Full Text] [Related]
23. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer.
Boudreaux KJ; Clark PE; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Chang SS
J Urol; 2009 Feb; 181(2):540-5; discussion 546. PubMed ID: 19084855
[TBL] [Abstract][Full Text] [Related]
24. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
25. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
26. [Clinical significance of the stereological estimation of mean nuclear volume in human bladder carcinoma--relation to tumor grade, stage and prognosis].
Fukuzawa S; Hashimura T; Horii Y; Yoshida O; Sasaki M; Yamabe H
Hinyokika Kiyo; 1992 Jan; 38(1):25-9. PubMed ID: 1546565
[TBL] [Abstract][Full Text] [Related]
27. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
29. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients.
Li CC; Chang TH; Wu WJ; Ke HL; Huang SP; Tsai PC; Chang SJ; Shen JT; Chou YH; Huang CH
Eur Urol; 2008 Nov; 54(5):1127-34. PubMed ID: 18243511
[TBL] [Abstract][Full Text] [Related]
30. The risk factor for urethral recurrence after radical cystectomy in patients with transitional cell carcinoma of the bladder.
Cho KS; Seo JW; Park SJ; Lee YH; Choi YD; Cho NH; Yang SC; Hong SJ
Urol Int; 2009; 82(3):306-11. PubMed ID: 19440019
[TBL] [Abstract][Full Text] [Related]
31. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma: analysis of patient outcomes.
Boudreaux KJ; Chang SS; Lowrance WT; Rumohr JA; Barocas DA; Cookson MS; Smith JA; Clark PE
Cancer; 2009 Feb; 115(4):770-5. PubMed ID: 19152431
[TBL] [Abstract][Full Text] [Related]
32. The impact factors on prognosis of patients with pT3 upper urinary tract transitional cell carcinoma.
Wu CF; Pang ST; Chen CS; Chuang CK; Chen Y; Lin PY
J Urol; 2007 Aug; 178(2):446-50, dicussion 450. PubMed ID: 17561129
[TBL] [Abstract][Full Text] [Related]
33. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
[TBL] [Abstract][Full Text] [Related]
34. Upper urinary tract recurrence after radical cystectomy for bladder cancer--who is at risk?
Volkmer BG; Schnoeller T; Kuefer R; Gust K; Finter F; Hautmann RE
J Urol; 2009 Dec; 182(6):2632-7. PubMed ID: 19836794
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy?
Segal R; Yafi FA; Brimo F; Tanguay S; Aprikian A; Kassouf W
BJU Int; 2012 Apr; 109(7):1026-30. PubMed ID: 21883838
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract.
Terakawa T; Miyake H; Muramaki M; Takenaka A; Hara I; Fujisawa M
Urology; 2008 Jan; 71(1):123-7. PubMed ID: 18242379
[TBL] [Abstract][Full Text] [Related]
37. Outcome of very large superficial bladder tumours: a 10-year experience.
Gupta SK; Parr NJ
Scand J Urol Nephrol; 2008; 42(3):243-8. PubMed ID: 18432531
[TBL] [Abstract][Full Text] [Related]
38. Grade 3 bladder cancer with lamina propria invasion (pT1): characteristics of tumor and clinical course.
Takashi M; Sakata T; Murase T; Hamajima N; Miyake K
Nagoya J Med Sci; 1991 Mar; 53(1-4):1-8. PubMed ID: 1805133
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy.
Gupta A; Lotan Y; Bastian PJ; Palapattu GS; Karakiewicz PI; Raj GV; Schoenberg MP; Lerner SP; Sagalowsky AI; Shariat SF;
Urology; 2008 Feb; 71(2):302-7. PubMed ID: 18308108
[TBL] [Abstract][Full Text] [Related]
40. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer.
Margel D; Tal R; Baniel J
J Urol; 2007 Dec; 178(6):2297-300; discussion 2300-1. PubMed ID: 17936837
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
